Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 9/20 | 0.48 |
| ▸ | MAOA | P21397 | 9/20 | 0.48 |
| ▸ | KDM1A | O60341 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15716390 | 1.00 | KDM4E (0.49) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL28218449 | 1.00 | KDM4E (0.49) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL1967702 | 0.86 | DPP4 (0.54) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL13484245 | 0.86 | KDM4E (0.46) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL19893577 | 0.85 | MAOA (0.47) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL5199579 | 0.85 | MAOA (0.47) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL1967275 | 0.85 | MAOA (0.47) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL5806555 | 0.85 | MAOA (0.47) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL19893576 | 0.85 | MAOA (0.47) | KDM4EMAPTHPGDMAOBMAOA | |
| SCHEMBL2239136 | 0.85 | MAOA (0.47) | KDM4EMAPTHPGDMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | KDM4E 3174/4885MAPT 3426/4885HPGD 3197/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | KDM4E 3174/4885MAPT 3426/4885HPGD 3197/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | KDM4E 3174/4885MAPT 3426/4885HPGD 3197/4885 |
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | KDM4E 2961/4885MAPT 2615/4885HPGD 2906/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | KDM4E 3174/4885MAPT 3426/4885HPGD 3197/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | KDM4E 2961/4885MAPT 2615/4885HPGD 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.